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Introduction: The aim of this study was to create a predictive score for yeast isolation in patients with complicated
non-postoperative intra-abdominal infections (CNPIAI) and to evaluate the impact of yeast isolation on outcome.
Methods: All patients with a CNPIAI undergoing emergency surgery over a three-year period were included in
the retrospective cohort (RC, n = 290). Patients with a yeast-positive peritoneal fluid culture (YP) were compared
with patients with a yeast-negative culture (YN). Multivariate logistic regression was used to identify factors independently
associated with yeast isolation and a predictive score was built. The score’s performance was then established in the
prospective cohort (PC, n = 152) over an 18-month period. Outcome of the whole cohort was evaluated and independent
risks factors of mortality searched.
Results: In the RC, 39 patients (13.4%) were YP. Four factors were independently associated with the YP group: length of
stay before surgery ≥48 h (odds ratio (OR) (95% confidence interval (CI)) = 3.1 (1.4 to 6.9), P = 0.004, 1 point), per-operative
cardiovascular failure (2.4 (1.1 to 5.8), P = 0.04, 1 point), generalized peritonitis (6.8 (2.7 to 16.7), P <0.001, 2 points) and
upper gastrointestinal tract perforation (2.5 (1.2 to 5.6), P = 0.02, 1 point). In the PC, the area under the curve (95%CI) of
the predictive score’s receiver operating characteristic curve was 0.79 (0.72 to 0.86). For predicting an intra-abdominal
candidiasis (IAC), a score ≥3 had a sensitivity of 0.60, a specificity of 0.84, a positive predictive value of 0.49 and a negative
predictive value of 0.89. Furthermore, yeast isolation was associated with worse outcome and independently associated
with mortality in the whole cohort (OR = 2.15; 95%CI (1.03 to 4.46), P = 0.04).
Conclusions: The new predictive score can be used to rule out intra-abdominal candidiasis and thus avoid the initiation of
antifungal treatment. It is suited to less severe infections than previously published scores. IAC is associated independently
with an increased mortality in this population.Introduction
The pathogenicity of yeasts isolated in the peritoneal fluid
of patients with complicated intra-abdominal infections
(and especially community-acquired infections (CAIs)) is
subject to debate. There are some data to suggest that
yeasts have an impact on the outcome in cases of pep-
tic ulcer perforation [1]. Non-postoperative nosocomial
intra-abdominal infections (NPNIAIs) share certain* Correspondence: dupont.herve@chu-amiens.fr
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the frequency of yeast isolation in peritoneal fluid sam-
ples. In view of the high mortality rate observed in pa-
tients with post-operative infections [3] and patients
with organ failure admitted to the intensive care unit
(ICU) [4], the pathogenicity of yeast in these contexts
has been investigated more. However, the guidelines on
the management of these types of infection are essen-
tially based on extrapolation of data on candidemia
[5,6]. Even though yeast intra-abdominal infections can
be candidemic [7], the frequency is low and the dis-
eases do not have the same course [8]. A number of
scores have been developed in order to predict the oc-
currence of candidemia in high-risk patients, includingl. This is an Open Access article distributed under the terms of the Creative
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and a clinical rule [11]. However, none of these scores is
suitable for complicated intra-abdominal infections. Fur-
thermore, each of these scores has a high negative predict-
ive value (NPV, for ruling out yeast infection) rather than a
high positive predictive value (PPV, for initiating treatment)
[12]. Ten years ago, Dupont et al. developed a score for se-
vere complicated intra-abdominal infections in the ICU
[13]. This is still the only available score with a moderately
good PPV and NPV [13]. However, it was developed in a
severe population of ICU patients. There are few data on
less severe patients having undergone emergency surgery.
The objectives of the present study were to (i) build a pre-
dictive score for yeast isolation in the peritoneal fluid of pa-
tients with complicated non-postoperative intra-abdominal
infections (CNPIAI) in a retrospective cohort of patients
and (ii) validate the score in a separate prospective cohort.
The new score will be compared with previously described
scores. The relationship between intra-abdominal candidia-
sis (IAC) and the outcomes for patients with complicated
CNPNIAIs was also evaluated.
Material and methods
Study design and patients
This study was conducted in three parts. In the first part
(score construction), patients with a CNPIAI and having
undergone emergency surgery in our tertiary university
hospital were retrospectively included over a three-year
period (from January 2009 to December 2011). Patients
with yeast-positive (YP) peritoneal fluid culture were com-
pared with patient with a yeast-negative (YN) culture. A
predictive score was built by taking account of factors in-
dependently associated with IAC in the cohort. In the sec-
ond part of the study (score validation), patients were
included in a prospective cohort over an 18-month period
(from January 2012 to June 2013). The performance of the
new score was compared with previously published pre-
dictive scores (Dupont et al. [13], Leon at al. [10] and
Paphitou et al. [14]). In the third part, the impact of IAC
on outcome in the whole cohort was assessed.
The study’s objectives and procedures were approved by
the local investigational review board (Commission d’E-
valuation Ethique de la Recherche Non Interventionnelle,
Amiens, France). In accordance with French legislation,
the need for informed consent was waived because of the
observational nature of the study.
Patients with infected acute pancreatitis, postoperative
nosocomial infections, acute trauma perforation <6
hours and primary peritonitis (such as infected ascites)
were not included in the study.
Surgery and microbiological management
Surgery was performed by an experienced, trained team
in accordance with the above-mentioned guidelines forthe treatment of complicated intra-abdominal infections
[15]. The definition of complicated intra-abdominal infec-
tion used is that presented in the Infectious Diseases
Society of America (IDSA) guidelines: ‘Complicated intra-
abdominal infection extends beyond the hollow viscus of
origin into the peritoneal space and is associated with either
abscess formation or peritonitis’ [6]. Either laparoscopy or
laparotomy was performed (depending on the diagnosis
and the surgeon’s choice). All peritoneal fluid samples were
sent for microbiological and mycological testing. Anti-
microbial therapy was initiated as soon as possible and in
accordance with local treatment protocols. Treatment of
yeast infection was only considered if the patient had organ
failure. At least one preoperative blood culture was avail-
able for each patient. The mycology department performed
yeast cultures and susceptibility testing. A strain of
Candida was considered resistant to fluconazole for a
minimum inhibitory concentration >32 μg.ml−1.
Definitions and data collection
The etiology of the intra-abdominal infection, the extent
of the infection (generalized or localized) and the perfor-
ation site were recorded. The hospital length of stay before
surgery was noted. Demographic data and the underlying
disease were noted from the patient’s medical records. A
number of severity scores were calculated: the American
Society of Anesthesiologist score [16], the Mannheim peri-
tonitis index [17], the Acute Physiology and Chronic
Health Evaluation II (APACHE II) score [18], the Simpli-
fied Acute Physiology Score II (SAPS II) [19] and the
Sepsis-related Organ Failure Assessment (SOFA) score
[20]. Cardiovascular failure was defined by the need for
norepinephrine during surgery (despite fluid challenge).
Respiratory failure was defined by the need for more than
24 hours of mechanical ventilation. The ICU admission
rate, lengths of stay (in the ICU or a hospital ward) and
in-hospital mortality were assessed.
Statistical analysis
Results are expressed as mean ± standard deviation (SD)
or number (proportion). First, patients in the YP group
were compared with those in the YN group via a chi-
squared test (with Yates’ correction, if necessary) for
qualitative variables and a two-sided t test for quantita-
tive variables. A multivariate stepwise logistic regression
model (backward Wald model) was built in order to
identify any independent factors for yeast isolation in pa-
tients with intra-abdominal infections. Only significant
variables (P <0.05) in a univariate analysis were included
in the multivariate model. All potential explanatory vari-
ables included in the multivariate analyses were subjected
to a collinearity analysis in a correlation matrix. Intercor-
related variables were not included in the multivariate
model (tolerance <0.3 and variance inflation factor >3).
Table 1 Location and etiologies of complicated
non-postoperative intra-abdominal infections in the
whole cohort of patients
Whole cohort
(n = 442)
Lower gastrointestinal tract 312 (70.6)
Appendicitis 133 (30.1)
Diverticulitis 75 (17)




Upper intestinal tract 130 (29.4)
Biliary tract 76 (17.2)
Ulcus disease 43 (9.7)
Ischemic 6 (1.4)
Miscellaneous 5 (1.0)
Results are expressed as the number (proportion, in %).
Table 2 Results of the peritoneal fluid cultures in the
whole cohort of patients with complicated non-
























Results are expressed as the number (proportion, in %). *Thirteen patients had
a pure culture of Candida (18.8% of the fungal infections).
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tervals (95%CIs) are reported. The constant (intercept)
was only included in the model when statistically signifi-
cant [21]. The Hosmer-Lemeshow test was used to assess
the model’s goodness of fit [21]. The statistical significance
of individual regression coefficients was assessed with the
Wald chi-squared test [21]. The model’s predicted prob-
abilities were validated with the c statistic (corresponding
to the model’s area under the curve (AUC)) [21].
A score was built according to the ORs in the multivari-
ate analysis and was tested in a receiver operating charac-
teristic (ROC) analysis [22]. The best score’s cutoff was
calculated for the best Youden index. The score’s perform-
ance was tested in a prospective (validation) cohort, ac-
cording to the same analysis. The AUC of the ROC curve
of new score was compared with the AUC of previously
published scores in the same cohort using Hanley and
McNeil tests.
A second multivariate analysis was performed to iden-
tify the impact of yeast isolation in mortality of the
whole cohort. The threshold for statistical significance
was set to P ≤0.05. Statistical analyses were performed
with PASW Statistics 18 software (IBM Inc., Chicago, IL,
USA) and MedCalc 12.7.5 software (MedCalc Software,
Ostend, Belgium).
Results
Four hundred and forty-four patients were included in
the study (290 in the retrospective cohort and 152 in the
prospective cohort). Location of perforation, main eti-
ologies and microbiological cultures of the peritoneal
fluid are exposed in Tables 1 and 2. Bacteremia occurred
in 9.3% of the patients and no candidemia was observed.
Predictive factors for yeast isolation
Two hundred and ninety patients were included in the
retrospective cohort. Of these, 39 (13.4%) had an intra-
abdominal candidiasis (72.5% of Candida albicans). Fif-
teen percent of the strains were fluconazole-resistant. The
demographic characteristics of the YP and YN groups are
summarized in Table 3. There were no significant inter-
group differences other than a higher proportion of pa-
tients on immunosuppression in the YP group (P = 0.006).
In all, 74.1% of the patients had a CAI; these were essen-
tially gallbladder perforations (n = 56, 19.3%), appendix
perforations (n = 90, 31.1%) and colon perforations (n =
81, 27.9%). There were marked intergroup differences in
the severity scores and types of infection (Table 3). Pa-
tients in the YP group were significantly more likely to
have worse severity scores (P <0.001 for all), NPNIAIs
(P <0.001), generalized infections (<0.001), upper gastro-
intestinal tract perforation (P <0.001) and ongoing anti-
microbial therapy (≥48 hours) (P = 0.01). The results of
the multivariate analysis are reported in Table 4. Four
Table 3 Demographic data for the retrospective cohort according of the presence (yeast positive) or absence
(yeast negative) of yeast in the peritoneal fluid culture
Yeast positive Yeast negative P value
(n = 39) (n = 251)
Age 65 ± 18 59 ± 22 0.08
Female gender 20 (51.3) 125 (49.8) 0.98
BMI (kg.m−2) 26.6 ± 7.2 25.9 ± 5.7 0.95
Underlying diseases
Prior abdominal surgery 7 (17.9) 46 (18.1) 0.87
Diabetes 7 (17.9) 40 (15.9) 0.93
Immunosuppression 7 (17.9) 12 (4.8) 0.006
Chronic cardiovascular disease 22 (56.4) 120 (47.8) 0.41
Chronic renal failure 3 (7.7) 9 (3.6) 0.15
ASA status 2.9 ± 0.6 2.5 ± 0.8 0.001
Mannheim peritonitis index score 22.9 ± 7.6 16.0 ± 8.1 <0.001
APACHE II score 14.6 ± 10.9 8.0 ± 7.9 <0.001
SAPS II score 36.2 ± 20.6 24.7 ± 15.2 <0.001
SOFA score 4.9 ± 6.5 1.9 ± 3 <0.001
Type of infection
Community-acquired 19 (48.7) 196 (78.1) <0.001
LOS ≥48 h before surgery 20 (51.3) 55 (21.9)
Generalized peritonitis 31 (79.5) 95 (37.8) <0.001
Upper gastrointestinal tract location 18 (46.2) 74 (29.6) <0.001
Ongoing AB ≥48 h 12 (30.8) 35 (13.9) 0.01
Results are expressed as the mean ± standard deviation or the number (proportion, in %). BMI, body mass index; ASA, American Society of Anesthesiology;
APACHE II, Acute Physiology and Chronic Health Evaluation II; SAPS II, Simplified Acute Physiology Score II; SOFA, Sepsis-related Organ Failure Assessment; LOS,
length of stay; AB, antimicrobial therapy.
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before surgery ≥48 h, per-operative cardiovascular failure,
generalized peritonitis and upper gastrointestinal tract
perforation. The model’s Wald chi-squared statistic was
50.2 (df = 5, P <0.001). The Hosmer-Lemeshow test statis-
tic was 9.69 (df = 6, P = 0.14). The model’s c statistic was
0.83 (0.77 to 0.89).Table 4 Multivariate analysis of factors independently
associated with an intra-abdominal candidiasis in the
retrospective cohort with CAIs and NPNIAIs
Parameters Adjusted OR 95%CI P value
Per-operative cardiovascular
failure
2.43 1.01 - 5.81 0.04
Upper gastrointestinal tract
perforation
2.53 1.15 - 5.55 0.02
LOS ≥48 h before surgery 3.15 1.45 - 6.89 0.004
Generalized peritonitis 6.78 2.75 - 16.68 <0.001
CAIs, community-acquired infections; NPNIAIs, non-postoperative nosocomial
intra-abdominal infections; OR, odds ratio; CI, confidence interval; LOS, length
of stay.Construction and validation of the score
A predictive score was built according to the ORs in the
multivariate analysis (Table 5). In the retrospective cohort,
the area (95%CI) under the curve was 0.82 (0.73 to
0.90), yielding the following characteristics for a score ≥3:
sensitivity = 0.75; specificity = 0.77; PPV= 0.34; NPV= 0.95;
positive likelihood ratio = 3.2; negative likelihood ratio = 0.34.
The score was validated in a prospective cohort of 152
patients. There were no significant demographic or clinical
differences between the retrospective and prospective co-
horts (Table 6), except for a slightly higher SOFA score inTable 5 Predictive score for intra-abdominal candidiasis
in complicated non-postoperative intra-abdominal
infections
Item Value
LOS ≥48 h before surgery 1 point
Per-operative cardiovascular failure 1 point
Generalized peritonitis 2 points
Upper gastrointestinal tract perforation 1 point
LOS, length of stay.
Table 6 Comparison of the construction and validation
cohorts
Construction cohort Validation cohort P value
(n = 290) (n = 152)
Age 60.2 ± 21.7 59.4 ± 27.8 0.74
Female gender 145 (50.0) 80 (52.6) 0.62




16.9 ± 8.4 17.8 ± 4.2 0.13
SOFA score 2.0 ± 3.9 2.5 ± 1.4 0.03
APACHE II score 8.9 ± 8.6 9.3 ± 7.1 0.57




215 (74.1) 114 (75.0) 0.91
ICU admission 93 (32.1) 57 (37.5) 0.29
Mortality 30 (10.3) 20 (13.2) 0.43
Results are expressed as the mean ± standard deviation or the number
(proportion, in %). BMI, body mass index; SOFA, Sepsis-related Organ Failure
Assessment; APACHE II, Acute Physiology and Chronic Health Evaluation II; IAC,
intra-abdominal candidiasis; ICU, intensive care unit.
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yeasts were isolated, with essentially the same distribution
as in the retrospective cohort (C. albicans: 62.5%) and the
same proportion of fluconazole resistance (15.6%). The pro-
portion of YP samples as a function of the score is shown
for each cohort in Figure 1. The score’s AUC of the ROC
curve for the prospective cohort was 0.79 (0.72 to 0.86). For
a predictive score ≥3, the sensitivity was 0.60, the specificity
was 0.84, the PPV was 0.49, the NPV was 0.90, the positive
likelihood ratio was 3.85 and the negative likelihood ratio
was 0.47. The AUC of the ROC curve of the new score isFigure 1 Comparison of the prevalence of a yeast-positive (YP) peritone
and in the prospective validation cohort (n = 152), as a function of the spresented in comparison with previously published scores of
Dupont et al. [13], Leon et al. [10] and Paphitou et al. [14]
in Figure 2. The new score had the best AUC when com-
pared with other scores. However, no statistical differences
were observed between the new score and Dupont’s score
(P = 0.15), the new score and Leon’s score (P = 0.17). The
former three scores were all significantly better than Paphi-
tou’s score (P = 0.0001; P = 0.006; P = 0.02, respectively).
Outcome of the whole cohort
Main outcomes when comparing YP and YN groups are
presented in Table 7. Briefly, patients with an IAC had
more complications, had undergone more relaparotomies,
and had more organ failure requiring ICU admission. Their
hospital length of stay was twice as high and mortality
three times higher (27.5% vs. 8.3%, P <0.001). Univariate
and multivariate analysis of mortality is exposed in Table 8.
Four independent factors of mortality in the whole cohort
were evidenced: an IAC, a Manheim peritonitis score ≥17,
an American Society of Anesthesiology (ASA) score ≥3
and a SOFA score ≥1. The model’s Wald chi-squared stat-
istic was 93.3 (df = 4, P <0.001). The Hosmer-Lemeshow
test statistic was 3.8 (df = 6, P = 0.694). The model’s c statis-
tic was 0.79 (0.73 to 0.85). For the population of patients
with IAC (n = 69), 52.2% were treated with an antifungal
drug (39% of azole and 61% of echinocandin). Mortality
rate was 21.2% in the group treated versus 33.3% in the
group not treated (P = 0.29).
Discussion
Our present results show that a YP peritoneal fluid cul-
ture is associated with worst outcomes and increased
mortality in patients with CNPIAI. The prevalence of
yeast isolation in this context is low (15.6%). Four parame-
ters were independently associated with IAC: length ofal fluid culture in the retrospective construction cohort (n = 290)
core.
Figure 2 Comparison of receiver operating characteristic curves between the new score and previously published one in the
prospective cohort (Dupont et al. [13], Leon et al. [10], Paphitou et al. [14]).
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failure, generalized peritonitis and upper gastrointestinal
tract perforation. The predictive score has a high NPV and
thus can be used to rule out the presence of yeast in the
peritoneal fluid. Hence, this score may constitute an easy-Table 7 Comparison of outcomes between yeast-positive and
non-postoperative intra-abdominal infections
Whole cohort Yeast positive
(n = 442) (n = 69)
Any complication 54 (63.8)






Cardiovascular failure 36 (52.2)
Respiratory failure 35 (50.7)
ICU admission 39 (56.5)
Duration of mechanical ventilation (d) 10.7 ± 14.9
ICU length of stay (d) 16.1 ± 16.4
Hospital length of stay (d) 20.5 ± 22.4
Mortality 19 (27.5)
Results are expressed as the mean ± standard deviation or the number (proportion,to-use bedside tool that enables the physician to avoid the
initiation of inappropriate antifungal treatment.
Although yeasts are undoubtedly pathogenic in postop-
erative infections [3], this question is subject to debate in
the context of CAIs and there are few data on this specificyeast-negative groups with complicated












9.5 ± 14.7 0.69
11.6 ± 13.9 0.11
13.2 ± 16.0 0.001
31 (8.3) <0.001
in %). ICU, intensive care unit.
Table 8 Predictive factors of mortality in the whole cohort of 442 patients with complicated non-postoperative
intra-abdominal infections
Parameters Univariate analysis Multivariate analysis
OR 95%CI P value AOR 95%CI P value
IAC 4.19 2.20-7.98 0.001 2.15 1.03-4.46 0.04
Ongoing AB ≥48 h 3.52 1.83-6.79 0.001 - - -
MPI score ≥17 7.96 3.31-19.10 0.001 3.22 1.26-8.25 0.02
ASA score ≥3 19.42 5.95-63.47 0.001 7.56 2.21-25.78 0.001
SOFA score ≥1 18.35 6.47-52.02 0.001 7.90 2.68-23.26 0.001
APACHE II score ≥7 19.22 5.88-62.82 0.001 - - -
OR, odds ratio; CI, confidence interval; AOR, adjusted odds ratio; IAC, intra-abdominal candidiasis; AB, antimicrobial therapy; MPI, Mannheim peritonitis index; ASA,
American Society of Anesthesiology; SOFA, Sepsis-related Organ Failure Assessment; APACHE II, Acute Physiology and Chronic Health Evaluation II.
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difference in outcome between YP and YN CAIs [3]. How-
ever, the study featured a small number of patients. In a
study of patients with organ failure admitted to the ICU, a
YP culture was found to be associated with elevated mor-
tality [4]. Another study reported a significantly greater
proportion of septic shock in CAIs when yeast was de-
tected in the peritoneal fluid culture [23]. The overall
prevalence of a YP culture in our study population (15.6%)
is similar to the mean value reported in the literature (with
values ranging from 4% to 43.4% in studies of CAIs)
[2,24]. The prevalence clearly depends on the study popu-
lation in question. For example, the prevalence was very
high in two studies that focused solely on peptic ulcer per-
forations [1,24]. Furthermore, yeast isolation was associ-
ated with increased morbidity and mortality in these
studies (21.7% vs. 3.4 % [1] and 33.3% vs. 14.6% [24] for
YP and YN patients, respectively).
In the present study, four parameters were found to be
independently associated with IAC of patients with a
CNPIAI. Interestingly, upper gastrointestinal tract per-
foration and per-operative cardiovascular failure were
previously included in a predictive score for severe intra-
abdominal infections in the ICU [4]. Another Spanish
study reported these two risk factors in 74 Candida
peritonitis patients [25]. The two other parameters in
the latter study (female gender and ongoing antimicro-
bial therapy for more than 48 hours) were not significant
in our study [4]. However, ongoing antimicrobial therapy
was associated with yeast isolation in our univariate ana-
lysis; this was probably due to the low prevalence of
antimicrobial therapy because few patients had hospital-
acquired infections. It has been well established that on-
going antimicrobial therapy is a recognized risk factor
for candidemia [26]. However, in the present study, hos-
pital length of stay ≥48 h before surgery was found to be
independently associated with yeast isolation. There are
no literature data on why yeast isolation is more fre-
quently associated with generalized peritonitis than with
localized infection. It could be only due to the majorimpact of appendicitis infections in CAI. The population
investigated in the present study is mild to moderate
with only a 33.9% rate of ICU admission and a low mor-
tality of 11.3%. It is very different to the Dupont et al.
[13] or Leon et al. [10] studies with a 100% rate of ICU
admission and reported mortality of 43% and 33%,
respectively.
The score developed in the present study has a good
NPV. It may be important to avoid the inappropriate ini-
tiation of antifungal treatments that are costly and
whose impact on resistance is not well known [27]. All
the previously published scores or clinical rules were de-
veloped to predict the occurrence of candidemia (even
in high-risk surgical patients) [9-11]. These scores have
much the same operational values as our present score -
notably with very high NPV for avoiding treatment. The
high NPV is essentially due to the low prevalence of the
disease. However, the predictive value of a score has
been shown to be better for severe intra-abdominal in-
fections in the ICU than previously described for candi-
demia, with a PPV of 67% and a NPV of 72% [13]. The
colonization index and the Candida score were recently
tested for the prediction of blood culture-negative IAC
but had very poor operational values [28]. Blood levels
of ß-glucan may be of value for the diagnosis of postop-
erative infections in high-risk surgical patients [28].
However, there are no data on the value of ß-glucan
levels in CAIs. Furthermore, it may not be enough to
know the change over time in ß-glucan levels in CAIs
because the physician has to decide at bedside whether
antifungal treatment must be initiated or not. We did
not have access to a ß-glucan assay during our study. It
has been suggested that a combination of high levels of
ß-glucan and the C. albicans germ tube antibody can
differentiate between Candida colonization and invasive
candidiasis in ICU patients with severe abdominal con-
ditions [29]. In the latter study, fewer than 50% of the
patients had CAIs. Furthermore, the study was designed
to assess the course of candidiasis in the ICU, rather
than to predict the presence of candidiasis on admission.
Dupont et al. Critical Care  (2015) 19:60 Page 8 of 9A worse outcome associated with YP culture of the
peritoneal fluid was evidenced in this study. Further-
more, it was independently associated with mortality. It
is the first report in the literature of such impact in mild
to moderate infections.
Our study had some potential limitations. First, this was
a single-center study. Nevertheless, our center is a large
tertiary-care hospital with an experienced, trained team for
the care of patients with complicated intra-abdominal in-
fections. Furthermore, peritoneal fluid samples were avail-
able for all patients and all were sent for microbiological
and mycological culture. However, the present study’s re-
sults must be validated in multicenter trials. Recently, the
sensitivity breakpoints for Candida spp. were modified ac-
cording to the species [30]. This study used previously
described breakpoints (>32 μg.ml−1) that could have under-
estimated the rate of strains resistant to fluconazole. Our
study focused on the development of a predictive score
and thus did not address the question of how best to treat
IAC. It was only associated with increased morbidity and
mortality in our population. The comparison of mortality
rates according to treatment or not in the group of patients
with IAC is not very relevant due to many confounding
factors and a clear lack of power. The American guidelines
for the treatment of abdominal candidiasis are essentially
derived from candidemia guidelines [6]. Recently, an Italian
group drew up a list of recommendations for the treatment
of IAC [5]. However, in view of the lack of scientific evi-
dence, the vast majority of guidelines are based on expert
opinion or extrapolation of data on candidemia [8]. Lastly,
the use of the new score is not well calibrated for critical
care patients because only one-third of the cohort was ad-
mitted to the ICU.
Conclusions
In conclusion, a score for predicting IAC was respectively
built and validated in retrospective and prospective co-
horts (featuring a total of 442 CNPIAIs). The new score
has a high NPV (for ruling out the need for antifungal
treatment at the bedside). It remains to be validated in
larger, multicenter cohorts of patients.
Key messages
 A simple clinical score at bedside may help to avoid
antifungal treatment in patients with CNPIAIs.
 The clinical score includes per-operative cardiovas-
cular failure (1 point), upper gastrointestinal tract
location of the perforation (1 point), length of stay
before surgery more than 48 hours (1 point)
and generalized peritonitis (2 points)
 Yeast isolation in patients with CNPIAIs is
associated with increased morbidity and
independently with increased mortality.Abbreviations
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negative; YP: yeast positive.
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